| High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival P Noble, M Vyas, A Al-Attar, S Durrant, J Scholefield, L Durrant British journal of cancer 108 (10), 2097-2105, 2013 | 67 | 2013 |
| Antigen loss variants: catching hold of escaping foes M Vyas, R Müller, E Pogge von Strandmann Frontiers in immunology 8, 252230, 2017 | 45 | 2017 |
| Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D … M Vyas, S Reinartz, N Hoffmann, KS Reiners, S Lieber, JM Jansen, ... Oncoimmunology 6 (9), e1339854, 2017 | 41 | 2017 |
| Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer M Vyas, U Koehl, M Hallek, EP von Strandmann Trends in molecular medicine 20 (2), 72-82, 2014 | 29 | 2014 |
| Extracellular matrix proteins regulate NK cell function in peripheral tissues MD Bunting, M Vyas, M Requesens, A Langenbucher, EB Schiferle, ... Science advances 8 (11), eabk3327, 2022 | 23 | 2022 |
| Kinesin-5 blocker monastrol protects against bortezomib-induced peripheral neurotoxicity I Bobylev, D Peters, M Vyas, M Barham, I Klein, EP von Strandmann, ... Neurotoxicity Research 32, 555-562, 2017 | 21 | 2017 |
| Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia M Vyas, AC Schneider, O Shatnyeva, KS Reiners, S Tawadros, S Kloess, ... Oncoimmunology 5 (9), e1211220, 2016 | 21 | 2016 |
| Natural killer cells suppress cancer metastasis by eliminating circulating cancer cells M Vyas, M Requesens, TH Nguyen, D Peigney, M Azin, S Demehri Frontiers in Immunology 13, 1098445, 2023 | 15 | 2023 |
| The extracellular matrix and immunity: Breaking the old barrier in cancer M Vyas, S Demehri Trends in Immunology 43 (6), 423-425, 2022 | 10 | 2022 |
| DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies OM Shatnyeva, HP Hansen, KS Reiners, M Sauer, M Vyas, ... Frontiers in Genetics 6, 128683, 2015 | 9 | 2015 |
| Triplebody mediates increased anti-leukemic reactivity of IL-2 activated donor natural killer (NK) cells and impairs viability of their CD33-expressing NK subset S Kloess, A Ede Valverde da Silva, O Oberschmidt, T Gardlowski, ... Frontiers in Immunology 8, 1100, 2017 | 8 | 2017 |
| Extracellular matrix–natural killer cell interactome: an uncharted territory in health and disease M Vyas, D Peigney, S Demehri Current Opinion in Immunology 78, 102246, 2022 | 3 | 2022 |
| In vivo gain-of-function screen identifies CREB5, a novel ECM modulator that promotes immunotherapy resistance via the Collagen-Lair1 axis P Tiwari, K Colvin, S Kim, A Kammula, S Anderson, OY Revach, M Vyas, ... CANCER IMMUNOLOGY RESEARCH 11 (12), 2023 | | 2023 |
| Abstract B021: In vivo gain-of-function screen identifies CREB5, a novel ECM modulator that promotes immunotherapy resistance via the Collagen-Lair1 axis P Tiwari, K Colvin, S Kim, A Kammula, S Anderson, OY Revach, M Vyas, ... Cancer Immunology Research 11 (12_Supplement), B021-B021, 2023 | | 2023 |
| NK cells lose their ability to control MHC-I-deficient tumor cells outside circulation. M Requesens, M Bunting, M Vyas, S Demehri CANCER IMMUNOLOGY RESEARCH 8 (3), 129-129, 2020 | | 2020 |
| Abstract B87: NK cells lose their ability to control MHC-I-deficient tumor cells outside circulation M Requesens, M Bunting, M Vyas, S Demehri Cancer Immunology Research 8 (3_Supplement), B87-B87, 2020 | | 2020 |
| Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset S Kloess, A Ede Valverde da Silva, O Oberschmidt, T Gardlowski, ... Frontiers in Immunology 9, 2326, 2018 | | 2018 |
| EFFECTS OF MONASTROL IN BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY I Bobylev, D Peters, M Vyas, M Barham, I Klein, EP von Strandmann, ... J. Peripher. Nerv. Syst. 22 (3), 244-246, 2017 | | 2017 |
| Development of novel trispecific immunoligands (triplebodies) to retarget natural killer cells against chronic lymphocytic leukemia M Vyas Universität zu Köln, 2016 | | 2016 |
| Harnessing NK cells to target chronic lymphocytic leukemia: design and efficacy of novel trispecific immunoligands M Vyas, PE von Strandmann Eur. J. Immunol. 46, 68-69, 2016 | | 2016 |
